Skip to main content
. 2016 Feb 29;352:i788. doi: 10.1136/bmj.i788

Fig 2.

Fig 2

 Distribution of FDA approved dose (green histogram) in the US population of cancer patients, and available combinations of full vial contents (red lines) to achieve that dose for bortezomib (top) and bendamustine (bottom)